PDF(Pubmed)
Abstract：
BACKGROUND: The role of beta calcitonin gene-related peptide (beta-CGRP) in gastrointestinal tract is obscure, but experimental models suggest an effect on the homeostasis of the intestinal mucosa. We measured beta-CGRP circulating levels in a large series of subjects with a recent diagnosis of inflammatory bowel disease (IBD), in order to assess the potential role of this neuropeptide in IBD pathogenesis.
METHODS: Morning serum beta-CGRP levels were measured by ELISA (CUSABIO, China) in 96 patients recently diagnosed of IBD and compared with those belonging from 50 matched healthy controls (HC) and 50 chronic migraine (CM) patients.
RESULTS: Beta-CGRP levels were lower in patients with IBD (3.1 ± 1.9 pg/mL; 2.9 [2.4-3.4] pg/mL) as compared to HC (4.7 ± 2.6; 4.9 [4.0-5.8] pg/mL; p < 0.001) and to CM patients (4.6 ± 2.6; 4.7 [3.3-6.2] pg/mL; p < 0.001). Beta-CGRP levels in CM were not significantly different to those of HC (p = 0.92). Regarding IBD diagnostic subtypes, beta-CGRP levels for ulcerative colitis (3.0 ± 1.9pg/mL; 2.5 [2.1-3.4] pg/mL) and Crohn\'s disease (3.3 ± 2.0 pg/mL; 3.2 [2.4-3.9] pg/mL) were significantly lower to those of HC (p < 0.01 and p < 0.05, respectively) and CM (p < 0.01 and p < 0.05, respectively).
CONCLUSIONS: We have found a significant reduction in serum beta-CGRP levels in patients with a recent diagnosis of all kinds of IBD as compared to two control groups without active intestinal disease, HC and CM, which may suggest a role for this neuropeptide in the pathophysiology of IBD. Our data indicate a protective role of beta-CGRP in the homeostasis of the alimentary tract.
METHODS: Morning serum beta-CGRP levels were measured by ELISA (CUSABIO, China) in 96 patients recently diagnosed of IBD and compared with those belonging from 50 matched healthy controls (HC) and 50 chronic migraine (CM) patients.
RESULTS: Beta-CGRP levels were lower in patients with IBD (3.1 ± 1.9 pg/mL; 2.9 [2.4-3.4] pg/mL) as compared to HC (4.7 ± 2.6; 4.9 [4.0-5.8] pg/mL; p < 0.001) and to CM patients (4.6 ± 2.6; 4.7 [3.3-6.2] pg/mL; p < 0.001). Beta-CGRP levels in CM were not significantly different to those of HC (p = 0.92). Regarding IBD diagnostic subtypes, beta-CGRP levels for ulcerative colitis (3.0 ± 1.9pg/mL; 2.5 [2.1-3.4] pg/mL) and Crohn\'s disease (3.3 ± 2.0 pg/mL; 3.2 [2.4-3.9] pg/mL) were significantly lower to those of HC (p < 0.01 and p < 0.05, respectively) and CM (p < 0.01 and p < 0.05, respectively).
CONCLUSIONS: We have found a significant reduction in serum beta-CGRP levels in patients with a recent diagnosis of all kinds of IBD as compared to two control groups without active intestinal disease, HC and CM, which may suggest a role for this neuropeptide in the pathophysiology of IBD. Our data indicate a protective role of beta-CGRP in the homeostasis of the alimentary tract.
摘要：
背景：β-降钙素基因相关肽（β-CGRP）在胃肠道中的作用尚不清楚，但是实验模型表明对肠粘膜的稳态有影响。我们测量了一系列最近诊断为炎症性肠病（IBD）的受试者的β-CGRP循环水平，为了评估这种神经肽在IBD发病机制中的潜在作用。
方法：采用酶联免疫吸附试验(CUSABIO,中国）在最近诊断为IBD的96例患者中，并与50名匹配的健康对照（HC）和50名慢性偏头痛（CM）患者进行了比较。
结果：IBD患者的β-CGRP水平低于HC（4.7±2.6；4.9[4.0-5.8]pg/mL；p<0.001）和CM患者（4.6±2.6；4.7[3.3-6.2]pg/mL；p<0.001）。CM中的β-CGRP水平与HC没有显着差异（p=0.92）。关于IBD诊断亚型，溃疡性结肠炎（3.0±1.9pg/mL;2.5[2.1-3.4]pg/mL）和克罗恩病（3.3±2.0pg/mL;3.2[2.4-3.9]pg/mL）的β-CGRP水平显着低于HC（分别为p<0.01和p<0.05）和CM（分别为p<0.01和p<0.05）。
结论：我们发现，与两个没有活动性肠道疾病的对照组相比，最近诊断为各种IBD的患者的血清β-CGRP水平显着降低，HC和CM，这可能表明这种神经肽在IBD的病理生理学中的作用。我们的数据表明β-CGRP在消化道稳态中具有保护作用。
方法：采用酶联免疫吸附试验(CUSABIO,中国）在最近诊断为IBD的96例患者中，并与50名匹配的健康对照（HC）和50名慢性偏头痛（CM）患者进行了比较。
结果：IBD患者的β-CGRP水平低于HC（4.7±2.6；4.9[4.0-5.8]pg/mL；p<0.001）和CM患者（4.6±2.6；4.7[3.3-6.2]pg/mL；p<0.001）。CM中的β-CGRP水平与HC没有显着差异（p=0.92）。关于IBD诊断亚型，溃疡性结肠炎（3.0±1.9pg/mL;2.5[2.1-3.4]pg/mL）和克罗恩病（3.3±2.0pg/mL;3.2[2.4-3.9]pg/mL）的β-CGRP水平显着低于HC（分别为p<0.01和p<0.05）和CM（分别为p<0.01和p<0.05）。
结论：我们发现，与两个没有活动性肠道疾病的对照组相比，最近诊断为各种IBD的患者的血清β-CGRP水平显着降低，HC和CM，这可能表明这种神经肽在IBD的病理生理学中的作用。我们的数据表明β-CGRP在消化道稳态中具有保护作用。
